Episode 25. Managing Acute Toxicities of CAR T-cell Therapy
Blood Cancer Talks · Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.
Here are some of the key articles we discussed:
1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.
https://pubmed.ncbi.nlm.nih.gov/36989488/
2. CAR-HEMATOTOX score:
https://pubmed.ncbi.nlm.nih.gov/34166502/
3. “How I treat cytopenias after CAR T-cell therapy”.
https://pubmed.ncbi.nlm.nih.gov/36800563/
4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):
https://pubmed.ncbi.nlm.nih.gov/36906275/
5. ASTCT consensus grading for CRS and ICANS:
https://pubmed.ncbi.nlm.nih.gov/30592986/
6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:
https://pubmed.ncbi.nlm.nih.gov/35696759/
7. Modified EASIX score for predicting CRS and neurotoxicity:
https://pubmed.ncbi.nlm.nih.gov/34432870/